MA27178A1 - Inhibiteurs de acc - Google Patents

Inhibiteurs de acc

Info

Publication number
MA27178A1
MA27178A1 MA27830A MA27830A MA27178A1 MA 27178 A1 MA27178 A1 MA 27178A1 MA 27830 A MA27830 A MA 27830A MA 27830 A MA27830 A MA 27830A MA 27178 A1 MA27178 A1 MA 27178A1
Authority
MA
Morocco
Prior art keywords
methanone
anthracene
carbonyl
bipiperidinyl
dimethylmorpholine
Prior art date
Application number
MA27830A
Other languages
English (en)
Inventor
David Austen Perry
Harold James Harwood Jr
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27178A1 publication Critical patent/MA27178A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Inorganic Insulating Materials (AREA)
  • Magnetic Heads (AREA)
  • Polishing Bodies And Polishing Tools (AREA)

Abstract

(cis)-(1'S,3'R)-anthracène-9-yl-{4-[3-(morpholine-4-carbonyl)-cyclohexyl]-pipérazine-1-yl}-méthanone ; (3R)-[1'-(2,6-diphénylpyridine-4-carbonyl)-[1,4']bipipéridinyl-3-yl] - (2-oxa-5-azabicyclo[2.2.1l]hept-5-yl) -méthanone ; (3R) -anthracène-9-yl [3- (méso-3, 5-diméthylmorpholine-4-carbonyl)-[1,4']bipipéridinyl-1'-yl]-méthanone ; (3R)-anthracène-9-yl[3-(3R,5R-diméthylmorpholine-4-carbonyl)-[1,4']bipipéridinyl-1'-yl]-méthanone ; anthracène-9-yl-[3-(morpholine-4-sulfonyl)-[1,4']bipipéridinyl-1'-yl]-méthanone ; (3R)-anthracène-9-yl-[3-(3S,5S-diméthylmorpholine-4-carbonyl)-[1,4']bipipéridinyl-1'-yl]-méthanone ; (3R)-anthracène-9-yl-{3-[3-(morpholine-4-carbonyl)-pipéridine-1-yl]-azétidine-1-yl}-méthanone ; ou les sels pharmaceutiquement acceptables desdits composés. 15. Composition pharmaceutique qui comprend un composé suivant la revendication 1, un de ses précurseurs médicamenteux, ou un sel pharmaceutiquement acceptable dudit composé ou dudit précurseur médicamenteux et un support, véhicule ou diluant pharmaceutiquement acceptable.
MA27830A 2002-02-27 2004-08-18 Inhibiteurs de acc MA27178A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36535802P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
MA27178A1 true MA27178A1 (fr) 2005-01-03

Family

ID=27766270

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27830A MA27178A1 (fr) 2002-02-27 2004-08-18 Inhibiteurs de acc

Country Status (20)

Country Link
US (1) US6979741B2 (fr)
EP (1) EP1478437B1 (fr)
KR (1) KR20040095239A (fr)
CN (1) CN1642599A (fr)
AT (1) ATE303178T1 (fr)
AU (1) AU2003248354A1 (fr)
CO (1) CO5601002A2 (fr)
DE (1) DE60301491T2 (fr)
EA (1) EA200400980A1 (fr)
ES (1) ES2246481T3 (fr)
HR (1) HRP20040716A2 (fr)
IL (1) IL163659A0 (fr)
IS (1) IS7391A (fr)
MA (1) MA27178A1 (fr)
NO (1) NO20044034L (fr)
NZ (1) NZ534582A (fr)
PL (1) PL372887A1 (fr)
TN (1) TNSN04164A1 (fr)
WO (1) WO2003072197A1 (fr)
ZA (1) ZA200406332B (fr)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006500315A (ja) * 2002-01-11 2006-01-05 アボット・ラボラトリーズ 糖尿病状態に用いるヒスタミン−３受容体リガンド
WO2004063715A2 (fr) * 2003-01-10 2004-07-29 The Trustees Of Columbia University In The City Of New York Procedes pour utiliser la structure cristalline du domaine de carboxyltransferase de l'acetyl-coa carboxylase, modulateurs de celle-ci et procedes informatiques
CA2515368A1 (fr) 2003-02-13 2004-08-26 Luciano Rossetti Regulation de la prise alimentaire et de la production de glucose par modulation des niveaux d'acyl-coa gras de chaine longue dans l'hypothalamus
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2004103993A1 (fr) 2003-05-14 2004-12-02 Syrrx, Inc. Inhibiteurs de dipeptidyl peptidase
EP1506967B1 (fr) 2003-08-13 2007-11-21 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidyl peptidase.
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1699777B1 (fr) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidylpeptidase
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0326029D0 (en) * 2003-11-07 2003-12-10 Astrazeneca Ab Chemical compounds
ES2291951T3 (es) * 2003-11-07 2008-03-01 F. Hoffmann-La Roche Ag Derivados de benzo (b) (1,4) dioxepina.
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MXPA06010571A (es) 2004-03-15 2007-02-16 Takeda Pharmaceutical Inhibidores de dipeptidil peptidasa.
US20050267221A1 (en) * 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
US7150969B2 (en) * 2004-06-04 2006-12-19 Rosetta Inpharmatics Llc Alternatively spliced isoform of acetyl-CoA carboxylase 2 (ACC2)
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CA2570637A1 (fr) * 2004-06-24 2006-02-02 Wenqing Yao Piperidines a substitution n et utilisation de ces dernieres en tant que substances pharmaceutiques
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US7618980B2 (en) * 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
WO2006019965A2 (fr) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Inhibiteurs de la dipeptidyl peptidase
EP1828192B1 (fr) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidyle peptidase
US7906645B2 (en) 2004-12-24 2011-03-15 Astrazeneca Ab Heterocyclic compounds as ccr2b antagonists
WO2006086464A2 (fr) 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones utilisees comme modulateurs de la 5ht
BRPI0613427A2 (pt) * 2005-07-19 2012-10-30 Merck & Co Inc composto ou seu sal ou éster, composição farmacêutica, agente terapêutico, e , uso do composto ou seu sal ou éster
US20100160255A1 (en) * 2005-07-29 2010-06-24 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
ME02005B (fr) 2005-09-14 2012-08-31 Takeda Pharmaceuticals Co Inhibiteurs de la dipeptidyl peptidase permettant de traiter le diabete
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
WO2007053499A2 (fr) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Composés pouvant être employés en tant qu'antagonistes de ccr2
US20100016289A1 (en) * 2005-11-01 2010-01-21 Kevin Sprott Compounds Useful as Antagonists of CCR2
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
JP2009526868A (ja) * 2006-02-15 2009-07-23 アボット・ラボラトリーズ 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
US8748627B2 (en) * 2006-02-15 2014-06-10 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2007112347A1 (fr) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
CA2648748A1 (fr) 2006-04-14 2007-10-25 Takeda Pharmaceutical Company Limited Compose heterocyclique azote
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
MY145447A (en) * 2006-09-13 2012-02-15 Takeda Pharmaceutical Use of 2-6(3-amino-piperidin-1-yl)-3-methyl-2, 4-dioxo-3, 4-dihydrp-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
AU2008205642B2 (en) 2007-01-12 2013-06-06 Msd K.K. Spirochromanon derivatives
WO2008090944A1 (fr) 2007-01-25 2008-07-31 Takeda Pharmaceutical Company Limited Composé à cycle spiro
WO2008103367A2 (fr) * 2007-02-20 2008-08-28 Sergey Kozmin Procédé permettant d'assembler des bibliothèques chimiques d'une grande pureté, et composés proapoptotiques découverts grâce à ce procédé
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
JP2010527360A (ja) * 2007-05-14 2010-08-12 ニューエラ・ファーマシューティカルズ・インコーポレーテッド 神経細胞の代謝低下の処置のためのアセチル−ｃｏａカルボキシラーゼの阻害剤
KR20100031528A (ko) 2007-06-01 2010-03-22 더 트러스티즈 오브 프린스턴 유니버시티 숙주세포 대사경로의 조절을 통한 바이러스 감염 치료
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
US8318762B2 (en) 2008-05-28 2012-11-27 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
JP5501256B2 (ja) 2008-07-04 2014-05-21 Ｍｓｄ株式会社 新規スピロクロマノンカルボン酸
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
EP2321341B1 (fr) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
US20100113473A1 (en) 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
CN102695708B (zh) 2009-11-10 2014-10-15 辉瑞大药厂 N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
SG183812A1 (en) 2010-03-19 2012-10-30 Pfizer 2,3 dihydro-1h-inden-1-yl- 2,7-diazaspiro [3.5] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
EA021698B1 (ru) * 2010-04-27 2015-08-31 Такеда Фармасьютикал Компани Лимитед Производные бициклических соединений и их применение в качестве ингибиторов acc
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
RS55224B1 (sr) 2010-09-30 2017-02-28 Pfizer N1-pirazolospiroketon acetil-coa karboksilaza inhibitori
PT2632925E (pt) 2010-10-29 2015-09-01 Pfizer Inibidores de n1/n2-lactama da acetil-coa carboxilase
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683703B1 (fr) 2011-03-08 2015-05-27 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
WO2012120058A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
RS54526B1 (sr) 2011-04-22 2016-06-30 Pfizer Inc. Upotreba derivata pirazolospiroketona kao inhibitora acetil-coa karboksilaze
CA2841757A1 (fr) 2011-07-15 2013-01-24 Etzer Darout Modulateurs de gpr 119
JP5647379B2 (ja) 2011-07-22 2014-12-24 ファイザー・インク キノリニルグルカゴン受容体モジュレーター
WO2013030713A1 (fr) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano[3,4-d][1,3]thiazine-2-amines
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
SG11201401531RA (en) 2011-11-11 2014-07-30 Pfizer 2-thiopyrimidinones
EP3628320B1 (fr) 2011-11-11 2022-03-16 Gilead Apollo, LLC Inhibiteurs d'acc et leurs utilisations
US8530460B2 (en) 2011-12-19 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
US8530461B2 (en) 2011-12-29 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
US8623860B2 (en) 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof
PE20142164A1 (es) 2012-04-06 2014-12-27 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6110937B2 (ja) 2012-05-04 2017-04-05 ファイザー・インク ＡＰＰ、ＢＡＣＥ１、およびＢＡＣＥ２の阻害剤としての複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
CA2882389A1 (fr) 2012-09-20 2014-03-27 Pfizer Inc. Composes d'hexahydropyrano[3,4-d][1,3]thiazine-2-amine alkyl-substitues
JP2016502978A (ja) 2012-12-11 2016-02-01 ファイザー・インク ＢＡＣＥ１の阻害剤としてのヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
CA2893333C (fr) 2012-12-19 2017-10-24 Pfizer Inc. Composes hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitues carbocycliques et heterocycliques
CA2897678A1 (fr) 2013-02-13 2014-08-21 Pfizer Inc. Composes hexahydropyrano [3,4-d][1,3] thiazin-2-amine substitues par un heteroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
SG11201506385WA (en) * 2013-03-18 2015-10-29 Genoscience Pharma Quinolines derivatives as novel anticancer agents
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
BR112016004118A2 (pt) 2013-09-12 2017-10-17 Pfizer uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
JP6348582B2 (ja) 2013-10-09 2018-06-27 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
EP3118192A4 (fr) 2014-03-14 2017-12-13 Takeda Pharmaceutical Company Limited Procédé de production d'un composé hétérocyclique
SG11201606779RA (en) 2014-03-17 2016-10-28 Pfizer Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
DK3126330T3 (en) 2014-04-04 2019-04-23 Pfizer BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
AU2015245260A1 (en) 2014-04-10 2016-10-06 Pfizer Inc. 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
WO2016092413A1 (fr) 2014-12-10 2016-06-16 Pfizer Inc. Composés indoliques et indazoliques qui activent l'ampk
WO2016103097A1 (fr) 2014-12-22 2016-06-30 Pfizer Inc. Antagonistes de récepteur ep3 de prostaglandine
BR112017022340A2 (pt) 2015-05-05 2018-07-10 Pfizer 2-tiopirimidinonas
EP3303303A1 (fr) 2015-05-29 2018-04-11 Pfizer Inc Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de l'enzyme vanine-1
BR112017026191B1 (pt) 2015-06-17 2023-10-10 Pfizer Inc Compostos tricíclicos inibidores de fosfodiesterase, sua composição farmacêutica e uso dos mesmos
WO2016203335A1 (fr) 2015-06-18 2016-12-22 Pfizer Inc. Nouvelles pyrido [2,3-b] pyrazinones utilisées en tant qu'inhibiteurs de bromodomaines de la famille bet
JP2018527337A (ja) 2015-08-13 2018-09-20 ファイザー・インク 二環式縮合ヘテロアリールまたはアリール化合物
EP3858825A1 (fr) 2015-08-27 2021-08-04 Pfizer Inc. Composés hétéroaryles bicycliques condensés en tant que modulateurs d'irak 4
WO2017037567A1 (fr) 2015-09-03 2017-03-09 Pfizer Inc. Régulateurs de la frataxine
WO2017051294A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-diméthyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides utiles comme inhibiteurs de bace
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
AU2016325665A1 (en) 2015-09-24 2018-03-08 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
MX2018006286A (es) 2015-11-25 2018-09-07 Gilead Apollo Llc Inhibidores de acc pirazolicos y usos de los mismos.
CA3005900C (fr) 2015-11-25 2023-10-31 Gilead Apollo, Llc Inhibiteurs d'acc a base de triazole et utilisations associees
EP3380478B1 (fr) 2015-11-25 2020-12-23 Gilead Apollo, LLC Inhibiteurs de l'acc à base d'esters et utilisations associées
JP2019503338A (ja) 2015-11-25 2019-02-07 ギリアド アポロ， エルエルシー ２，４−ジオキソ−１，４−ジヒドロチエノ［２，３−ｄ］ピリミジンの誘導体を含む殺真菌組成物
TN2018000198A1 (en) 2015-12-29 2019-10-04 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
CN108699078A (zh) 2016-03-02 2018-10-23 吉利德阿波罗公司 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
EP3266454A1 (fr) * 2016-07-07 2018-01-10 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Inhibiteurs d'acc pour leur utilisation dans le traitement de maladies mycobactériennes
BR112019000589A2 (pt) 2016-07-14 2019-04-24 Pfizer Inc. pirimidina carboxamidas como inibidores da enzima vanina-1
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
EP4424364B1 (fr) 2017-03-28 2026-01-21 Gilead Sciences, Inc. Combinaisons pour une utilisation dans le traitement de la cirrhose et de la fibrose du foie
WO2019133445A1 (fr) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles utilisés en tant qu'inhibiteurs de vanin-1
WO2020033919A1 (fr) 2018-08-10 2020-02-13 Diapin Therapeutics, Llc Tri-peptides et traitement de troubles métaboliques, cardiovasculaires et inflammatoires
AU2019329884B2 (en) 2018-08-31 2022-01-27 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
WO2020102575A1 (fr) 2018-11-16 2020-05-22 Inception Ibd, Inc. Aminothiazoles hétérocycliques et leurs utilisations
EP4578460A3 (fr) 2019-05-20 2025-08-27 Pfizer Inc. Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinées à être utilisées dans le traitement de la nash/nafld et de maladies associées
FI4097099T3 (fi) 2020-02-07 2024-07-30 Gasherbrum Bio Inc Heterosyklisiä glp-1-agonisteja
PL4143183T3 (pl) 2020-04-29 2026-03-02 Gasherbrum Bio, Inc. Heterocykliczni agoniści glp-1
CN114105947B (zh) * 2020-08-27 2025-04-22 鲁南制药集团股份有限公司 一类喹啉衍生物
WO2023169456A1 (fr) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Agonistes hétérocycliques de glp-1
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024118524A1 (fr) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Composés d'azaindole et leur utilisation en tant qu'inhibiteurs de phosphodiestérase
JP2026501171A (ja) 2022-12-15 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド Ｇｌｐ－１アゴニスト活性を有する化合物の塩および固体形態

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2325358C (fr) * 1999-11-10 2005-08-02 Pfizer Products Inc. Amides de l'acide 7-¬(4'-trifluoromethylbiphenyl-2-carbonyl)amino|-quinoleine-3-carboxylique et methodes pour inhiber la secretion d'apolipoproteine b
US6509358B2 (en) * 2000-07-17 2003-01-21 Wyeth Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US20030171588A1 (en) * 2002-03-07 2003-09-11 Kahl Jeffrey D. 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof

Also Published As

Publication number Publication date
IS7391A (is) 2004-08-09
ZA200406332B (en) 2005-09-28
EP1478437A1 (fr) 2004-11-24
KR20040095239A (ko) 2004-11-12
US6979741B2 (en) 2005-12-27
ATE303178T1 (de) 2005-09-15
NZ534582A (en) 2006-03-31
AU2003248354A1 (en) 2003-09-09
PL372887A1 (en) 2005-08-08
US20030187254A1 (en) 2003-10-02
ES2246481T3 (es) 2006-02-16
EA200400980A1 (ru) 2005-02-24
TNSN04164A1 (fr) 2007-03-12
WO2003072197A1 (fr) 2003-09-04
NO20044034L (no) 2004-11-24
CO5601002A2 (es) 2006-01-31
DE60301491D1 (en) 2005-10-06
HRP20040716A2 (en) 2005-02-28
EP1478437B1 (fr) 2005-08-31
DE60301491T2 (de) 2006-05-18
IL163659A0 (en) 2005-12-18
CN1642599A (zh) 2005-07-20

Similar Documents

Publication Publication Date Title
MA27178A1 (fr) Inhibiteurs de acc
EP1076055B1 (fr) Derives de 1- (1-substituee-4-piperidinyle)methyle]-4-piperidine, procede de production de ceux-ci, compositions medicinales contenant ces composes et intermediaires de ces composes
FI95572C (fi) Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US6465474B1 (en) 1,3-diheterocyclic metalloprotease inhibitors
HUP0301459A2 (en) Chemical compounds process for producing them and pharmaceutical compositions containing them
US20090181939A1 (en) Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders
NO20080416L (no) Forbedrede prosesser for fremstilling av Ezetimibe
HU221309B1 (en) Substituted azetidinone compounds useful as hypocholesterolemic agents, pharmaceutical compositions containing the same, intermediates and process for producing them
LV11687B (en) Substituted morpholine derivatives and their use as therapeutic agents
NZ530221A (en) Substituted anilinic piperidines as MCH selective antagonists
PE20050020A1 (es) DERIVADOS 4-(2-OXO-2,3-DIHIDRO-1-H-IMIDAZO[4,5-b]PIRIDIN-1-IL)-N-(2-OXO-AZEPAN-3-IL)PIPERIDINIL-1-CARBOXAMIDA SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR CGRP
US6121272A (en) Bidentate metalloprotease inhibitors
SK283860B6 (sk) Sírne deriváty azetidínových zlúčenín, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
AR049540A1 (es) Derivados de quinazolindiona como inhibidores del parp; metodos para su preparacion; composiciones farmaceuticas que los contienen como ingrediente activo y su uso en medicamentos para el tratamiento o prevencion del cancer.
HUT76275A (en) Cyclic amide derivatives, pharmaceutical compositions containing them and process for producing them
RU2008126391A (ru) Производные 1,5-замещенного индол-2-иламида
ATE519486T1 (de) Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer
JP2009539833A5 (fr)
AR072163A1 (es) Derivados de arilpirrolidinil y piperidinil-cetonas, composiciones farmaceuticas que los contienen, un metodo para el tratamiento o la prevencion de enfermedades y el uso del compuesto para la fabricacion de medicamentos
KR20010108403A (ko) 중추신경계 질병의 치료를 위한1-아렌설포닐-2-아릴-피롤리딘 및 피페리딘 유도체
CA2256438C (fr) Derives d'amidine aromatique utiles en tant qu'inhibiteurs selectifs de la thrombine
MX2007011694A (es) Derivados de pirrolidina 3,4-sustituida para el tratamiento de hipertension.
US9346786B2 (en) Pyrrolidine compounds
CZ285593B6 (cs) Způsob výroby (S)-3-amino-1-substituovaných pyrrolidinů
RU99109018A (ru) N-замещенные азагетероциклические соединения